Orion Portfolio Solutions LLC Purchases New Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Orion Portfolio Solutions LLC purchased a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,919 shares of the company’s stock, valued at approximately $239,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares during the last quarter. Innealta Capital LLC bought a new stake in Amphastar Pharmaceuticals in the second quarter worth about $55,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. bought a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $78,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of recent analyst reports. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $60.33.

Amphastar Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:AMPH opened at $39.39 on Friday. The business’s 50 day moving average is $46.63 and its 200 day moving average is $44.56. The stock has a market cap of $1.89 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the transaction, the director now owns 31,471 shares of the company’s stock, valued at approximately $1,535,784.80. This trade represents a 13.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at $3,900,522.90. The trade was a 6.51 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,533 shares of company stock worth $1,987,482. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.